Aanjaneya Lifecare gets certificate of suitability for two bulk drugs

29 Jun 2011 Evaluate

Mumbai based Aanjaneya Lifecare has received the certificate of suitability (CEP) from EDQM for two of its bulk drugs Quinine Sulphate & Quinine Hydrochloride. As one of world’s largest producers of Quinine Salts, this certification opens the gates for a huge market in Europe for Aanjaneya Lifecare.

The anti-Malarial segment is fast growing segment with large generic players from Europe including Teva, Actavis, Sanofi Aventis, Mylan etc being the dominant players. Aanjaneya has commenced supply of product Quinine Sulphate to pharmaceutical major Teva earlier this year.

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (API). APIs, also known as bulk drugs‘ or bulk actives‘ are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. The company specializes in anti-malaria drugs and Finished Dosage Forms (FDFs) for various therapeutic segments.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×